Expanded blood borne virus testing in a tuberculosis clinic. A cost and yield analysis - 01/03/15








Summary |
Objectives |
Testing for HIV is a standard of care for people with active tuberculosis (TB). People investigated for TB in the UK often originate from areas with a high prevalence of HIV and other blood borne viruses (BBV). However, assessment for these infections is patchy. We determined the yield and costs of different testing strategies for BBV in a UK TB clinic.
Methods |
Since 2009, it has been routine to test all TB clinic attendees. Demographic, clinical and virological data were retrospectively extracted from patient notes and hospital databases.
Results |
Over 3 years, 1036 people were assessed in the TB service. 410 had a final diagnosis of active TB. HIV testing of the latter population diagnosed 27 new HIV cases at a cost of £3017. When BBV testing was offered to all clinic attendees, a further 6 (total 33) new HIV, 5 Hepatitis B (HBV) and 2 Hepatitis C (HCV) diagnoses were made at a total cost of £22,170.
Conclusions |
We have identified previously undiagnosed HIV, HBV and HCV in a TB clinic population. Our data suggest that despite increasing upfront expense, the associated yield argues strongly for BBV testing to be offered to all patients being investigated for possible TB, irrespective of their final diagnosis.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Offering universal testing in a UK TB clinic revealed new HIV, Hepatitis B & C. |
• | The number needed to test per positive HIV result was 22 in all attendees. |
• | All cases of hepatitis B infection (5/598) were in non-UK born. |
Keywords : Tuberculosis, HIV infection, Hepatitis C virus, Hepatitis B virus, Tuberculosis management
Plan
Vol 70 - N° 4
P. 317-323 - avril 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?